{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T23:08:08Z","timestamp":1773788888999,"version":"3.50.1"},"reference-count":38,"publisher":"Japanese Society of Internal Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,1,1]]},"DOI":"10.2169\/internalmedicine.5120-24","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T18:07:48Z","timestamp":1750874868000},"page":"118-125","source":"Crossref","is-referenced-by-count":1,"title":["Retrospective Study of 68 Patients with Rheumatoid Arthritis-associated Lymphoproliferative Diseases Treated with Methotrexate"],"prefix":"10.2169","volume":"65","author":[{"given":"Yuko","family":"Asanuma","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Yamaji","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Fries JF. Current treatment paradigms in rheumatoid arthritis. Rheumatology (Oxford) 39 (Suppl 1): 30-35, 2000.","DOI":"10.1093\/oxfordjournals.rheumatology.a031492"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Aga AB, Lie E, Uhlig T, et al. Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010. Ann Rheum Dis 74: 381-388, 2015.","DOI":"10.1136\/annrheumdis-2013-204020"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Haugeberg G, Hansen IJ, Soldal DM, Sokka T. Ten years of change in clinical disease status and treatment in rheumatoid arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway. Arthritis Res Ther 17: 219, 2015.","DOI":"10.1186\/s13075-015-0716-0"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Raheel S, Matteson EL, Crowson CS, Myasoedova E. Improved flare and remission pattern in rheumatoid arthritis over recent decades: a population-based study. Rheumatology (Oxford) 56: 2154-2161, 2017.","DOI":"10.1093\/rheumatology\/kex352"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 386: 258-265, 2015.","DOI":"10.1016\/S0140-6736(14)61704-9"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Yamakawa N, Fujimoto M, Kawabata D, et al. A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders. J Rheumatol 41: 293-299, 2014.","DOI":"10.3899\/jrheum.130270"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Tokuhira M, Saito S, Okuyama A, et al. Clinicopathologic investigation of methotrexate-induced lymphoproliferative disorders, with a focus on regression. Leuk Lymphoma 59: 1143-1152, 2018.","DOI":"10.1080\/10428194.2017.1369073"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Mancuso S, Carlisi M, Santoro M, Napolitano M, Raso S, Siragusa S. Immunosenescence and lymphomagenesis. Immun Ageing 15: 22, 2018.","DOI":"10.1186\/s12979-018-0130-y"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sarkozy C, Salles G, Falandry C. The biology of aging and lymphoma: a complex interplay. Curr Oncol Rep 17: 32, 2015.","DOI":"10.1007\/s11912-015-0457-x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Baecklund E, Ekbom A, Spar\u00e9n P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 317: 180-181, 1998.","DOI":"10.1136\/bmj.317.7152.180"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54: 692-701, 2006.","DOI":"10.1002\/art.21675"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Wolfe F. Inflammatory activity, but not methotrexate or prednisone use predicts non-Hodgkins lymphoma in rheumatoid arthritis: a 25-year study of 1,767 RA patients. Arthritis Rheum 41: 188, 1998.","DOI":"10.1002\/1529-0131(199806)41:6<1072::AID-ART14>3.0.CO;2-G"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165: 2337-2344, 2005.","DOI":"10.1001\/archinte.165.20.2337"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Rezk SA, Weiss LM. Epstein-Barr virus-associated lymphoproliferative disorders. Hum Pathol 38: 1293-1304, 2007.","DOI":"10.1016\/j.humpath.2007.05.020"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Fugl A, Andersen CL. Epstein-Barr virus and its association with disease - a review of relevance to general practice. BMC Fam Pract 20: 62, 2019.","DOI":"10.1186\/s12875-019-0954-3"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Silman AJ, Petrie J, Hazleman B, Evans SJ. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 47: 988-992, 1988.","DOI":"10.1136\/ard.47.12.988"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Engels EA, Cerhan JR, Linet MS, et al. Immune-related conditions and immune-modulating medications as risk factors for non-Hodgkin&apos;s lymphoma: a case-control study. Am J Epidemiol 162: 1153-1161, 2005.","DOI":"10.1093\/aje\/kwi341"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ichikawa A, Arakawa F, Kiyasu J, et al. Methotrexate\/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol 91: 20-28, 2013.","DOI":"10.1111\/ejh.12116"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kurita D, Miyoshi H, Ichikawa A, et al. Methotrexate-associated lymphoproliferative disorders in patients with rheumatoid arthritis: clinicopathologic features and prognostic factors. Am J Surg Pathol 43: 869-884, 2019.","DOI":"10.1097\/PAS.0000000000001271"},{"key":"20","unstructured":"20. Hoshida Y, Xu JX, Fujita S, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 34: 322-331, 2007."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Tokuhira M, Tanaka Y, Takahashi Y, et al. The clinical impact of absolute lymphocyte count in peripheral blood among patients with methotrexate - associated lymphoproliferative disorders. J Clin Exp Hematop 60: 41-50, 2020.","DOI":"10.3960\/jslrt.19039"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Saito R, Tanaka M, Ito H, et al. Overall survival and post-spontaneous regression relapse-free survival of patients with lymphoproliferative disorders associated with rheumatoid arthritis: a multi-center retrospective cohort study. Mod Rheumatol 32: 50-58, 2022.","DOI":"10.1080\/14397595.2020.1866837"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Nakano K, Tanaka Y, Saito K, et al. Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders in patients treated with methotrexate: a retrospective, multi-center descriptive study. Mod Rheumatol 32: 41-49, 2022.","DOI":"10.1080\/14397595.2020.1847775"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Nakano K, Saito K, Nawata A, et al. Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders. Mod Rheumatol 31: 94-100, 2021.","DOI":"10.1080\/14397595.2020.1741870"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Kuramoto N, Saito S, Fujii T, et al. Characteristics of rheumatoid arthritis with immunodeficiency-associated lymphoproliferative disorders to regress spontaneously by the withdrawal of methotrexate and their clinical course: a retrospective, multicenter, case-control study. Mod Rheumatol 32: 24-31, 2022.","DOI":"10.1080\/14397595.2021.1879362"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Salloum E, Cooper DL, Howe G, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 14: 1943-1949, 1996.","DOI":"10.1200\/JCO.1996.14.6.1943"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Baird RD, van Zyl-Smit RN, Dilke T, Scott SE, Rassam SM. Spontaneous remission of low-grade B-cell non-Hodgkin&apos;s lymphoma following withdrawal of methotrexate in a patient with rheumatoid arthritis: case report and review of the literature. Br J Haematol 118: 567-568, 2002.","DOI":"10.1046\/j.1365-2141.2002.03619.x"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Takada H, Kaneko Y, Nakano K, et al. Clinicopathological characteristics of lymphoproliferative disorders in 232 patients with rheumatoid arthritis in Japan: a retrospective, multicenter, descriptive study. Mod Rheumatol 32: 32-40, 2022.","DOI":"10.1080\/14397595.2021.1899570"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Honda S, Sakai R, Inoue E, et al. Association of methotrexate use and lymphoproliferative disorder in patients with rheumatoid arthritis: Results from a Japanese multi-institutional retrospective study. Mod Rheumatol 32: 16-23, 2022.","DOI":"10.1080\/14397595.2020.1869370"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Saito S, Kaneko Y, Yamaoka K, et al. Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate. Rheumatology (Oxford) 56: 940-946, 2017.","DOI":"10.1093\/rheumatology\/kex002"},{"key":"31","unstructured":"31. Shiroky JB, Frost A, Skelton JD, Haegert DG, Newkirk MM, Neville C. Complications of immunosuppression associated with weekly low dose methotrexate. J Rheumatol 18: 1172-1175, 1991."},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Kamel OW, van de Rijn M, Weiss LM, et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 328: 1317-1321, 1993.","DOI":"10.1056\/NEJM199305063281806"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Rizzi R, Curci P, Delia M, et al. Spontaneous remission of &quot;methotrexate-associated lymphoproliferative disorders&quot; after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature. Med Oncol 26: 1-9, 2009.","DOI":"10.1007\/s12032-008-9069-8"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Hashimoto A, Chiba N, Tsuno H, et al. Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population. J Rheumatol 42: 564-571, 2015.","DOI":"10.3899\/jrheum.140533"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Shimizu Y, Nakajima A, Inoue E, et al. Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort. Clin Rheumatol 36: 1237-1245, 2017.","DOI":"10.1007\/s10067-017-3634-5"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Katsuyama T, Sada KE, Yan M, et al. Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents. Mod Rheumatol 27: 773-777, 2017.","DOI":"10.1080\/14397595.2016.1259714"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Fujimoto K, Hatanaka KC, Hatanaka Y, et al. Association of Epstein-Barr virus with regression after withdrawal of immunosuppressive drugs and subsequent progression of iatrogenic immunodeficiency-associated lymphoproliferative disorders in patients with autoimmune diseases. Hematol Oncol 38: 799-807, 2020.","DOI":"10.1002\/hon.2790"},{"key":"38","doi-asserted-by":"publisher","unstructured":"38. Takahashi C, Kaneko Y, Okano Y, et al. Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study. RMD Open 3: e000363, 2017.","DOI":"10.1136\/rmdopen-2016-000363"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/1\/65_5120-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T03:26:16Z","timestamp":1767410776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/1\/65_5120-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5120-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"article-number":"5120-24"}}